Article
Application of carbon nanotubes as drug delivery carriers is stalled by uncertainties over their distribution and toxicity in vivo . Here, the authors use animal models to show that, while the bulk of nanotubes is renally cleared, a fraction can be eliminated through an alternative hepatobiliary pathway.
Nature Communications doi: 10.1038/ncomms12343
Authors: Simone Alidori, Robert L. Bowman, Dmitry Yarilin, Yevgeniy Romin, Afsar Barlas, J. Justin Mulvey, Sho Fujisawa, Ke Xu, Alessandro Ruggiero, Vladimir Riabov, Daniel L. J. Thorek, Hans David S. Ulmert, Elliott J. Brea, Katja Behling, Julia Kzhyshkowska, Katia Manova-Todorova, David A. Scheinberg, Michael R. McDevitt